Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Other Non-Current Liabilities (2016 - 2025)

Traws Pharma (TRAW) has disclosed Other Non-Current Liabilities for 11 consecutive years, with $11000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $11000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $11000.0, a N/A change, with the full-year FY2024 number at $42.5 million, changed N/A from a year prior.
  • Other Non-Current Liabilities was $11000.0 for Q3 2025 at Traws Pharma, up from $8000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $42.5 million in Q4 2024 to a low of $8000.0 in Q2 2025.
  • A 3-year average of $7.3 million and a median of $342000.0 in 2021 define the central range for Other Non-Current Liabilities.
  • Biggest YoY gain for Other Non-Current Liabilities was 261.36% in 2021; the steepest drop was 128.45% in 2021.
  • Traws Pharma's Other Non-Current Liabilities stood at $530000.0 in 2021, then soared by 7917.74% to $42.5 million in 2024, then plummeted by 99.97% to $11000.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Other Non-Current Liabilities are $11000.0 (Q3 2025), $8000.0 (Q2 2025), and $154000.0 (Q1 2025).